Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily

Executive Summary

FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.


Related Content

Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk
MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes
Exubera Gone, But Not Forgotten: FDA Imposes REMS, Mandates Trials
Pfizer Reports Lung Cancer Development In Some Exubera Users
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer Plans Exubera “Full Court Press”’ In 2007 After 2006 Stumbles
Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts